Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

252.11 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Nov 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about ResMed Inc. Common Stock

< Previous 1 2 3 Next >
News headline image
Vaping Expected to Increase COPD Health and Economic Burden by 2050
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its Board
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
From ResMed Inc.
Via GlobeNewswire
News headline image
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound. 
Via MarketBeat
News headline image
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia
ResMed studies presented at SLEEP 2024 also revealed a 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean, and a higher rate of depression in women with OSA 
From ResMed Inc.
Via GlobeNewswire
News headline image
Developed in Collaboration with Leading Scientists, New ResMed-Supported Research at ATS 2024 Provides Evidence of the Effectiveness and Critical Role of Positive Airway Pressure Therapy
From ResMed Inc.
Via GlobeNewswire
News headline image
ATS 2024: New ResMed-Supported Research Shows Increasing Prevalence of Obstructive Sleep Apnea and Critical Role of PAP Therapy
From ResMed Inc.
Via GlobeNewswire
News headline image
MatrixCare Joins Health Gorilla’s Qualified Health Information Network (QHIN) to Enhance Patient Data Access
The alliance with Health Gorilla will provide MatrixCare customers with more than 220 million patient records to streamline workflows and improve patient outcomes. 
From MatrixCare
Via GlobeNewswire
News headline image
ResMed Announces Participation in the RBCCM Global Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis
From ResMed Inc.
Via GlobeNewswire
News headline image
Introducing the AirFit F40: Experience Unprecedented Freedom with the Comfort and Optimized Seal Performance of ResMed’s Smallest Full-Face CPAP Mask
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed’s New AirCurve™ 11 Bilevel Devices Enable Healthcare Providers to Make Informed Decisions about Care, Deliver Personalized Support, and Drive Positive Therapy Outcomes for Patients with Sleep Apnea
From ResMed Inc.
Via GlobeNewswire
News headline image
MatrixCare Earns Three 2024 Best in KLAS Awards
MatrixCare has been named a market leader by KLAS Research for its Home Health EHR in three Categories: Home Health – Independent – Large, Home Health – Independent – Small, and Hospice – Independent 
From MatrixCare
Via GlobeNewswire
News headline image
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
From ResMed Inc.
Via GlobeNewswire
News headline image
HCA Healthcare Rallies: Weight-loss drugs really a big threat?
HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges. 
Via MarketBeat
Topics ETFs
News headline image
ResMed to Report Second Quarter Fiscal 2024 Earnings on January 24, 2024
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Announces Participation in the 42nd Annual J.P. Morgan Healthcare Conference
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices
ResMed’s masks with magnets are safe when used in accordance with the updated Instructions for Use 
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Secures Significant Victory in Patent Fight Against New York University
From ResMed Inc.
Via GlobeNewswire
News headline image
Study Estimates a 23% Increase in COPD by 2050, Representing 600 Million Patients Globally
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Adopts New Operating Model to Accelerate Long-term Growth
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2024
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed to Report First Quarter Fiscal 2024 Earnings on October 26, 2023
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Announces Participation in Upcoming Conferences
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2023
From ResMed Inc.
Via GlobeNewswire
News headline image
ResMed to Report Fourth Quarter Fiscal 2023 Earnings on August 3, 2023
From ResMed Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.